Plus Therapeutics (NASDAQ:PSTV) Posts Earnings Results

Plus Therapeutics (NASDAQ:PSTV) announced its quarterly earnings results on Thursday. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.28, FiscalAI reports. The business had revenue of $1.37 million for the quarter.

Plus Therapeutics Trading Down 11.2%

Plus Therapeutics stock opened at $0.26 on Friday. The company’s 50-day moving average price is $0.32 and its two-hundred day moving average price is $0.48. Plus Therapeutics has a 52 week low of $0.16 and a 52 week high of $2.08. The stock has a market cap of $36.36 million, a price-to-earnings ratio of -0.14 and a beta of 0.79.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in shares of Plus Therapeutics during the second quarter valued at approximately $41,000. Altium Capital Management LLC purchased a new stake in Plus Therapeutics in the 3rd quarter valued at about $628,000. Scientech Research LLC acquired a new position in Plus Therapeutics during the 3rd quarter valued at about $100,000. Susquehanna International Group LLP bought a new stake in Plus Therapeutics during the third quarter worth about $46,000. Finally, Geode Capital Management LLC raised its stake in shares of Plus Therapeutics by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after purchasing an additional 589,544 shares during the period. Institutional investors and hedge funds own 3.28% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Lake Street Capital began coverage on shares of Plus Therapeutics in a report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $1.00 price objective (down from $2.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. Ascendiant Capital Markets reduced their price target on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. D. Boral Capital reduced their price objective on shares of Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Plus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $5.80.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.